FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. 0180.0063	SERIAL NO. 10/800,362
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANTS PARDRIDGE et al.	
	FILING DATE March 12, 2004	GROUP 1653

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,372,250	04--16-02	Pardridge	424	450	
	5,154,924	10-13-92	Friden	424	179.1	
	5,182,107	01-26-96	Friden	424	179.1	
	5,527,527	06-18-96	Friden	424	178.1	
	5,672,688	09-30-97	Friden et al.	530	350	
	5,833,988	11-10-98	Friden	424	178.1	
	5,977,307	11-02-99	Friden et al.	530	350	
	10/025,732		Pardridge et al.			12-09-01
	10/647,197		Pardridge et al			08-20-03

FOREIGN PATENT DOCUMENTS						TRANSLATION	
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Ram, Z. et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. *Nat. Med.* **3**, 1354-1361 (1997)
	Driesse, M.J., et al. Intracerebral injection of adenovirus harboring the HSVtk gene combined with ganciclovir administration: toxicity study in non-human primates. *Gene Ther.* **5**, 1122-1129 (1998).
	Dewey, R.A., et al. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. *Nat. Med.* **5**, 1256-1263.
	Twombly, R. For gene therapy, now-quantified risks are deemed troubling. *J. Natl Cancer Inst.* **95**, 1032-1033 (2003).
	Nakai, H., Montini, E., Fues, S., Storm T.A., Grompe, M., Kay, M.A. AAV serotype 2 vectors preferentially integrate into active genes in mice. *Nal. Genet.* **34**, 297-302 (2003).
	McManus, M.T. & Sharp, P.A. Gene silencing in mammals by small interfering RNAs. *Nat. Rev. Genet.* **3**, 737-747 (2002).
	Elbashir, S.M., Harborth, J., Weber, K., and Tuschl, T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. *Methods* **26**, 199-213 (2002).
	Verma, I.M., and Somia, N. Gene therapy - promises, problems and prospects. *Nature* **389**,

EXAMINER	DATE CONSIDERED 2/13/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. 0180.0063	SERIAL NO. 10/800,362
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANTS PARDRIDGE et al.	
	FILING DATE March 12, 2004	GROUP 1653

		239-242 (1997).
		Kuan, C.T., Wikstrand, C.J. & Bigner, D.D. EGF mutant receptor vIII as a molecular target in cancer therapy. *Endocr. Relat. Cancer* **8**, 83-96 (2001).
		Nicholson, R.I., Gee, J.M., and Harper, M.E. EGFR and cancer prognosis. *Eur. J. Cancer* **37** Suppl 4, S9-15 (2001).
		Heimberger, A.B. et al. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). *Clin. Cancer Res.* **8**, 3496-3502 (2002).
		Mishima, K., et al. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. *Cancer Res.* **61**, 5349-5354 (2001).
		Moroni, M.C., Willingham, M.C., and Beguinot, L. EGF-R antisense RNA blocks expression of the epidermal growth factor receptor and suprresses the transforming phenotype of a human carcinoma cell line. *J. Biol. Chem.* **267**, 2714-2722 (1992).
		Zhang, Y., Lee, H.J., Boado, R.J., & Pardridge, W.M. Receptor-mediated delivery of an antisense gene to human brain cancer cells. *J. Gene Med.* **4**, 183-194 (2002).
		Zhang, Y., Zhu, C. & Pardridge, W.M. Antisense gene therapy of brain cancer with an artificial virus gene delivery system. *Mol. Ther.* **6**, 67-72 (2002).
		Zhang, Y., Boado, R.J. & Pardridge, W.M. Marked enhancement in gene expression by targeting the human insulin receptor. *J. Gene Med.* **5**, 157-163 (2003).
		Snudden, D.K., Smith, P.R., Lai, D., Ng, M.H. & Griffin, B.E. Alterations in the structure of the EBV nuclear antigen, EBNA1, in epithelial cell tumours. *Oncogene* **10**, 1545-1552 (1995).
		Nagy, P., Arndt-Jovin, D.J. & Jovin, T.M. Small interfering RNAs suppress the expression of endogenous and GFP-fused epidermal growth factor receptor (erbB1) and induce apoptosis in erbB1-overexpressing cells. *Exp Cell Res* **285**, 39-49 (2003).
		Zhang, Y., Boado, R.J. & Pardridge, W.M. In vivo knock-down of gene expression in brain cancer with intravenous RNAi in adult rats. *J. Gene Med.*, **5**, 1039-1045 (2003).
		Wong, A.J., et al. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. *Proc. Natl. Acad. Sci. USA* **84**, 6899-6903 (1987).
		Libermann, T.A., Nusbaum, H.R., Razon, N., et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumors of glial origin.

EXAMINER	DATE CONSIDERED 2/14/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. 0180.0063	SERIAL NO. 10/800,362
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANTS PARDRIDGE et al.	
	FILING DATE March 12, 2004	GROUP 1653

		Nature **313**, 144-147 (1985).
		Pardridge, W.M. Drug and gene delivery to the brain: the vascular route. *Neuron* **36**, 555-558 (2002).
		Shi, N. & Pardridge, W.M. Non-invasive gene targeting to the brain. *Proc. Natl. Acad. Sci., U.S.A.* **97**, 7567-7572 (2000).
		Pardridge, W.M. Drug and gene targeting to the brain with molecular Trojan horses. *Nature Reviews-Drug Discovery* **1**, 131-139 (2002).
		Makrides, S.C. Components of vectors for gene transfer and expression in mammalian cells. *Protein Expr. Purif.* **17**, 183-202 (1999).
		Lee, H.J., Engelhardt, B., Lesley, J., Bickel, U. & Pardridge, W.M. (2000). Targeting rat anti-mouse transferrin receptor monoclonal antibodies through the blood-brain barrier in the mouse. *J. Pharmacol. Exp.* Ther. **292**, 1048-1052.
		Pardridge, W.M., Kang, Y.-S., Buciak, J.L. & Yang, J. (1995). Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. *Pharm. Res.* **12**, 807-816.
		Paddison, P., Caudy, A., Bernstein, E., Hannon, G., & Conklin, D. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. *Genes Dev.* **16**, 948-958 (2002).
		Yu, J.Y., Taylor,J., DeRuiter, S.L., Vojtek, A.B. & Turner, D.L. Simultaneous inhibition of GSK3alphna and GSK3beta using hairpin siRNA expression vectors. *Mol. Ther.* **7**, 228-236 (2003).
		Hernandez, M., Barrero, M.J., Crespo, M.S. & Nieto, M.L. (2000). Lysophosphatidic acid inhibits Ca^{2+} signaling in response to epidermal growth factor receptor stimulation in human astrocytoma cells by a mechanism involving phospholipase $C_{\square}$ and a $G_{\square i}$ protein. *J. Neurochem.* **75**, 1575-1582.
		Stout,C.E., Costantin, J.L., Naus, C.C., & Charles, A.C. (2002). Intercellular calcium signaling in astrocytes via ATP release through connexin hemichannels. *J. Biol. Chem.* **277**, 10482-10488.
		Lal, S. et al. An implantable guide-screw system for brain tumor studies in small animals. *J. Neurosurg.* **92**, 326-333 (2000).

EXAMINER	DATE CONSIDERED 2/13/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY DOCKET NO. 0180.0063	SERIAL NO. 10/800,362
	APPLICANTS PARDRIDGE et al.	
	FILING DATE March 12, 2004	GROUP 1653

		Kurihara, A. & Pardridge, W.M. Imaging brain tumors by targeting peptide radiopharmaceuticals through the blood-brain barrier. *Canc. Res.* **54**, 6159-6163 (1999).
		Luwor, R.B. et al. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor (EGFR) but not wild-type EGFR. *Cancer Res.* 61, 3496-3502 (2002).
		Lal, A. et al. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. *Cancer Res.* **62**, 5355-5361 (2001).
		Zhang, Y., Schlachetzki, F. & Pardridge, W.M. Global non-viral gene transfer to the primate brain following intravenous administration. *Mol. Ther.* **7**, 11-18 (2003).
		Coloma, M.J. et al. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. *Pharm. Res.* **17**, 266-274 (2000).
		Pardridge, W.M. *Brain Drug Targeting: The Future of Brain Drug Development.* Cambridge University Press, Cambridge, United Kingdom, pp 1-370 (2001).
		Traxler, P. et al. Tyrosine kinase inhibitors: from rational design to clinical trials. *Medicinal Research Reviews*, **21**, 499-512 (2001
		Clark, A.F. and Yorio, T. Ophthalmic drug discovery. *Nature Reviews Drug Discovery*, **2**, 448-459 (2003).

2/13/06

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.